Plasma free metanephrines are the gold-standard biochemical test for pheochromocytoma and...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-METANEPHRINES-PHEO-VHL-MEN2-SURVEILLANCE |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-05-18 | actionability review required |
| Enfermedades | DIS-PHEOCHROMOCYTOMA |
| Fuentes | SRC-ENDOCRINE-SOCIETY-MEN-2023 SRC-NCCN-KIDNEY-2025 SRC-NCCN-NET-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-METANEPHRINES-PLASMA-PHEO |
|---|---|
| Variante | Metanefrinas libres de plasma — feocromocitoma/paraganglioma de vigilancia en portadores de VHL/MEN2/SDH |
| Enfermedad | DIS-PHEOCHROMOCYTOMA |
| El nivel de ESCAT | IIIA |
| Combinaciones recomendadas | Elevación confirmada en el portador sindrómico: abdomen de RMN + 68GA-DOTATATO PET → adrenalectomía (ahorramiento de corticales si riesgo bilateral) o resección de paraganglioma, Equivocal: prueba de supresión de clonidina O Metanefrinas fraccionadas por vía urinaria de 24 horas confirman |
| Monoterapia contraindicada | Do not initiate beta-blockade for PPGL hypertension before adequate alpha-blockade (phenoxybenzamine 10-14 days) — risk of hypertensive crisis from unopposed alpha stimulation |
| Resumen de las pruebas | Plasma free metanephrines are the gold-standard biochemical test for pheochromocytoma and paraganglioma (PPGL) — sensitivity ~96-99%, specificity ~85-95% (lower with sympathomimetic / tricyclic / acetaminophen interferents and improper supine sampling). Used for annual lifelong surveillance in confirmed carriers of VHL (Type 2A/2B/2C), MEN2A/MEN2B (RET-codon-stratified onset), and SDHB/SDHC/SDHD/SDHA per Endocrine Society MEN 2023 and NCCN Kidney 2025 (VHL component). Elevation >3-4× upper limit highly suggestive of PPGL; intermediate elevation prompts clonidine-suppression test or 24-hour urinary fractionated metanephrines. Positive biochemistry triggers MRI abdomen + 68Ga-DOTATATE PET (or I-123 MIBG). Biochemistry directs adrenalectomy / paraganglioma resection planning. ESCAT IIIA — biomarker directs curative-intent surgery scheduling in syndromic carriers. |
Notas
STUB pending two-Co-Lead signoff. SDH (B/C/D/A) carrier surveillance Indication entities are pending authoring (closest existing: none yet for SDH; future IND-SDH-CARRIER-SURVEILLANCE). VHL classification (Type 1 vs Type 2A/2B/2C) determines pheo surveillance need — Type 1 lacks pheochromocytoma, Type 2 has it as defining feature. Render layer should flag concurrent sympathomimetic / tricyclic / acetaminophen use, supine-sample status, and renal function — all affect interpretation.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.